TME Pharma: Fast Track designation in glioblastoma

(CercleFinance.com) - TME Pharma announces that the US FDA has granted Fast Track designation to its NOX-A12, in combination with radiotherapy and bevacizumab, for use in the treatment of aggressive adult brain cancer.


This designation for newly-diagnosed, chemotherapy-resistant glioblastoma with measurable residual tumor post-surgery, follows the FDA's recent approval of the IND application for a Phase 2 study.

Fast Track designation aims to bring new drugs deemed essential to treat serious diseases and unmet medical needs to patients more quickly.

Copyright (c) 2024 CercleFinance.com. All rights reserved.